Leadership

Theodore (Ted) T. Ashburn, M.D., Ph.D.
President, CEO

Theodore (Ted) T. Ashburn, M.D., Ph.D. - President and CEO at Oncorus

Theodore (Ted) T. Ashburn, M.D., Ph.D.

President, CEO

Christophe Quéva, Ph.D.
Chief Scientific Officer

Christophe Quéva, Ph.D. - Chief Scientific Officer at Oncorus

Christophe Quéva, Ph.D.

Chief Scientific Officer

Lorena Lerner, Ph.D.
Senior Director, Molecular Biology

Lorena Lerner, Ph.D. - Senior Director, Molecular Biology

Lorena Lerner, Ph.D.

Senior Director, Molecular Biology

Theodore (Ted) T. Ashburn, M.D., Ph.D. - President and CEO at Oncorus

Theodore (Ted) T. Ashburn, M.D., Ph.D.
President, CEO

Before becoming Oncorus’ President, CEO and a member of its Board of Directors, Ted was Head of Oncology Development at Moderna Therapeutics where he was responsible for overall design, integration and execution of Moderna’s clinical-stage oncology programs. Prior to this role, he led the development of Moderna’s Personalized Cancer Vaccine programs. Previously, Ted was Senior Vice President of Product Strategy and Operations at Dicerna Pharmaceuticals and also the Global Product Head for Leukine® (sargramostim) and Elitek®/Fasturtec® (rasburicase) for Sanofi Oncology. In this latter role, Dr. Ashburn provided global leadership for R&D and global marketing and led regional commercial teams to identify, develop, prioritize and execute new commercialization and life-cycle management strategies to drive growth. He was also responsible for negotiating and implementing Sanofi’s 2013 supply, stockpiling and R&D contract with the U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA).

Ted joined Sanofi Oncology from Genzyme’s Corporate Development group where he led business development efforts for several of Genzyme’s franchises including transplant, oncology and rare diseases and was responsible for Genzyme’s 2009 deal with ViroPharma. Prior to joining Genzyme, he worked for privately held Dynogen Pharmaceuticals, Inc. and the venture capital firm Oxford Bioscience Partners. While at Oxford he co-founded both Dynogen and BrainCells, Inc. and led investments in Alantos Pharmaceuticals (acquired in June, 2007 by Amgen for $300 million in cash) and superDimension, Ltd. (acquired by Covidien in March, 2012 for more than $300 million). Before joining Oxford, Ted started his career at Pfizer Inc. where he was involved in the analysis of several acquisition and new business opportunities including Pfizer’s acquisition of Warner-Lambert in 2001.

Ted graduated magna cum laude from Ball State University where he studied chemistry and computer science. He earned his M.D. from Harvard Medical School and Ph.D. in organic chemistry from the Massachusetts Institute of Technology.

Christophe Quéva, Ph.D. Chief Scientific Officer at Oncorus

Christophe Quéva, Ph.D.
Chief Scientific Officer

Christophe Quéva, Ph.D., is Chief Scientific Officer and Senior Vice President, Research. Christophe is responsible for directing and advancing the company’s development program based on its next-generation immunotherapy platform of oncolytic viruses. An industry veteran, Christophe has nearly two decades’ immuno-oncology experience and successful portfolio-building track record from target identification and development through regulatory approval.

Prior to joining Oncorus, Christophe was Chief Scientific Officer at iTeos Therapeutics where his responsibilities included leading the generation of an innovative immuno-oncology portfolio of small molecule and antibody programs and overseeing the company’s translational medicine strategy for its A2A antagonist and TIGIT programs. Before iTeos, he held successive senior positions at AstraZeneca, Amgen and Gilead Sciences where he led or supported drug discovery programs for oncology and inflammatory diseases, from target selection to commercial approval for small molecules and biologics.

A holder of five patents and widely published, Christophe trained as a post-doctoral fellow at the Fred Hutchinson Cancer Research Center in Seattle after receiving his Ph.D. in Life and Health Sciences from the University of Lille, France.

Lorena Lerner, Ph.D. - Senior Director, Molecular Biology at Oncorus

Lorena Lerner, Ph.D.
Senior Director, Molecular Biology

Lorena Lerner Ph.D. is the Senior Director of Molecular Biology at Oncorus, where she is leading the efforts to engineer more potent and safer novel armed oncolytic viral vectors for the treatment of solid tumors.

Lorena is an experienced cancer biologist with a proven track record of managing and advancing projects, from early discovery into clinical development. Most recently, Lorena served as Director of Biology at Quiet Therapeutics, where she was responsible for leading the development of proprietary nanotechnology platform, identifying potent immunotherapy target candidates and optimizing vector design. Prior to Quiet, she served as Director of Target Discovery at Scholar Rock and held positions of increasing responsibilities at AVEO Oncology, where she pioneered and executed the development of AV-380, a cancer cachexia program targeting GDF15, from target identification, validation and antibody discovery through preclinical development and out-licensing enterprises.

Lorena received an MSc in Molecular Biology and a PhD in Biochemistry from University of Buenos Aires. She completed post-doctoral research fellowship in Molecular and Cellular Biology with Professor James E. Darnell at Rockefeller University. Her academic training focused in the field of gene regulation and cancer molecular biology. Lorena is a co-inventor of numerous patents and high-impact, peer-reviewed manuscripts and abstracts.